CD4 and asthma: In our study, we observed significant mediation effects where 1‐myristoyl‐2‐arachidonoyl‐GPC (14:0/20:4) levels mediated a substantial proportion of the effect of CD3 on CD28+ CD4+ T cells on asthma risk.